Abstract:Objective In our previous work, naltrexone, a common opioid receptor antagonist was found to be able to inhibit transplantation rejection. Here, we profound this work by using a specific opioid δ receptor antagonist naltrindole to explore the mechanism of the transplantation rejection related to opioid.Methods A transplantation model was used in the in vivo experiments, in which the cardiac tissue of newborn C57 mouse was transplanted into subcutis of the ear of Balb/c mouse. Mixed and cultured together, lymphocytes from two different strains of mice were used in the in vitro experiments. 3H TdR uptake (Bq) was measured to show the mixed lymphocyte reaction. The total RNA of the mixed lymphocytes cultured for certein time was hybridized with [ 32 P] PPE cDNA probe.Results (1)The survival of the transplanted tissues of naltrindole administrated group was significantly longer than that of naltrexone administrated group. (2) Treated with naltrexone or naltrindole, the proliferation of the mixed lymphocytes was inhibited in dose dependent style.And the inhibitory effect of naltrindole was greater than that of naltrexone. (3) It was also found that enkephalin increased the mixed lymphocyte reaction at the early stage of culturing in a concentration dependent biphasic manner, and nal trindole could totally antagonize its effect .(4) There was transcription of PPE mRNA in mixed lymphocytes cultured after certain time (10, 20, 40 and 60 h). Induced immune reaction and its endogenou ligand of this effect was most probably enkephalin.Conclusions (1) The results suggest that δ opioid receptor is involved in the antigen induced immune reaction and its endogenou ligand of this effect is probably enkephalin. (2) The activated immune cells in rejection is likely to produce enkephalin, which works as an stimulating factor for rejecting immune reaction.

Exploring the Function of (+)-Naltrexone Precursors: Their Activity as TLR4 Antagonists and Potential in Treating Morphine Addiction

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators

Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Pharmacological Characterization of the Opioid Inactive Isomers (+)-Naltrexone and (+)-Naloxone As Toll-Like Receptor 4 Antagonists

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Effect and Mechanism of Opioid Receptor Antagonist on Allograft Rejection

Exploring Naltrexamine Derivatives Featuring Azaindole Moiety Via Nitrogen-Walk Approach to Investigate Their in Vitro Pharmacological Profiles at the Mu Opioid Receptor

Methylation Products of 6Β- N-Heterocyclic Substituted Naltrexamine Derivatives As Potential Peripheral Opioid Receptor Modulators.

6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Stereoselective Syntheses of 3-Dehydroxynaltrexamines and N-methyl-3-dehydroxynaltrexamines.

Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry.

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.

Opioid Receptor Selectivity Profile Change Via Isosterism for 14-O-substituted Naltrexone Derivatives.

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

Blocking Potential Metabolic Sites on NAT to Improve Its Safety Profile While Retaining the Pharmacological Profile

Design and Synthesis of a Bivalent Ligand to Explore the Putative Heterodimerization of the Mu Opioid Receptor and the Chemokine Receptor CCR5.